Application of epilupine and its derivatives in the preparation of drugs against Alzheimer's disease
By using epilupinine and its derivatives as drug components, the existing anti-Alzheimer's disease drugs have been solved, and the effect of improving memory and reducing inflammation in the brain is achieved, providing a kind of effect Safe and effective treatment plan.
Patent Information
- Application Number
- CN202311554585.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-11-21
AI Technical Summary
The existing anti-Alzheimer's disease drugs are not ideal, cannot cure the disease, have great side effects, are expensive, difficult to widely popularize, and lack safe and effective preventive or interventional drugs.
Epilupine and its derivatives are used as drug components to reduce the level of inflammatory factors in the brain and relieve anxiety by improving mice's memory and spatial learning ability.
Epilulinine and its derivatives significantly improved the memory and spatial learning ability of Alzheimer's disease model mice, reduced brain inflammation, had small side effects, and had small doses of medication, which had significant therapeutic effects.
Smart Images

Figure CN117482089B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomedicine, and in particular to the application of epilupine and its derivatives in the preparation of anti-Alzheimer's disease drugs. Background Art
[0002] Alzheimer's disease (AD) is a chronic degenerative disease of the central nervous system characterized by progressive cognitive dysfunction, which gradually affects the ability to live daily. The global prevalence of AD among people over 65 years old is 4% to 7%, accounting for 60% to 80% of all causes of dementia, and the prevalence of AD doubles with every 6.1 years of age. With the aging of the population, the incidence and prevalence of AD have increased dramatically, and the resulting burden on families and society has become increasingly heavy.
[0003] However, the pathogenesis of AD is still unclear, and clinical drug treatment methods are limited. At present, the most widely used anti-Alzheimer's disease drugs in clinical practice are mainly acetylcholine esterase inhibitors (AChEI) (such as donepezil hydrochloride, rivastigmine bitartrate, etc.) and N-methyl-D-aspartate (NMDA) receptor blockers (such as memantine hydrochloride, etc.), but the effects of these drugs are not ideal. They can only alleviate symptoms, but cannot control the disease, cannot cure AD, and cannot even delay the development of AD. In addition, the side effects of drugs are large, and some patients are difficult to tolerate clinically. It can be seen that the development of safe and effective drugs for the prevention or intervention of AD is the focus and hotspot of AD research at this stage. In recent years, new drugs targeting Aβ protein such as aducanumab and lencanumab have also been approved for the treatment of AD, but such drugs are relatively expensive and difficult to be widely popularized in the short term. Therefore, finding new anti-AD drugs with good compliance, fewer side effects and high cost-effectiveness has great clinical significance and is also the main direction of anti-AD drug research and development.
[0004] Epilupinine (1-Epilupinine), also known as epilupinin, is isolated from Lupinus polyphyllus, a plant of the genus Lupinus in the Leguminosae family. Epilupinine is a quinolizidine alkaloid component with a molecular formula of C 10 H 19 NO, molecular weight is 169.26, melting point is 77-78℃, soluble in chloroform, methanol and ethanol. Subacute toxicity experiments have shown that epilupine has no significant effect on the bone marrow, liver, kidney and other functions of mice. So far, there has been no report on epilupine as an active ingredient to prevent or treat Alzheimer's disease. Summary of the invention
[0005] The purpose of the present invention is to provide the use of epilupine and its derivatives in the preparation of anti-Alzheimer's disease drugs, so as to provide new drugs for preventing or treating Alzheimer's disease, improving patients' cognitive dysfunction and improving patients' memory.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides the use of epilupine and its derivatives in the preparation of anti-Alzheimer's disease drugs, wherein the structural formula of the epilupine is:
[0008]
[0009] Preferably, the derivatives include organic acid or inorganic acid salt products of epilupine, and esterification products or etherification products of the 11-hydroxyl site of epilupine.
[0010] Preferably, the drug also includes a drug component that has a positive effect on combating Alzheimer's disease.
[0011] Preferably, the pharmaceutical ingredients having a positive effect on combating Alzheimer's disease include acetylcholinesterase inhibitors or N-methyl-D-aspartate receptor blockers.
[0012] Preferably, the acetylcholinesterase inhibitor comprises rivastigmine, galantamine or donepezil.
[0013] Preferably, the N-methyl-D-aspartate receptor blocker comprises memantine.
[0014] Preferably, the pharmaceutical ingredient having a positive effect on combating Alzheimer's disease also includes huperzine A or mannitol.
[0015] Preferably, the drug component having a positive effect on combating Alzheimer's disease also includes Aβ or Tau protein targeting drugs.
[0016] Preferably, the Aβ or Tau protein targeting drug includes Aducanumab, Donanemab or Lencanumab.
[0017] The present invention provides the use of epilupine (1-EPILUPININE) and its derivatives in drugs for preventing or treating Alzheimer's disease. The present invention has found that the use of epilupine or its derivatives at a dosage of 2.5-5 mg / kg can improve the memory and spatial learning ability of AD model mice, shorten the latency of AD model mice to find the platform in the spatial exploration experiment of the Morris water maze experiment, and increase the number of times they cross the platform. Secondly, in the open field experiment, it was found that the positive control drug cholinesterase inhibitor (donepezil) can significantly reduce the movement distance of mice in the open field and affect the motor ability of mice, while epilupine and its derivatives do not affect the movement distance of mice and have little effect on the motor ability of mice. At the same time, epilupine and its derivatives can increase the number of times and movement distance of mice entering the central area, and relieve the anxiety of AD model mice. Further studies have found that epilupine and its derivatives can reduce the level of pro-inflammatory factors in the brain of AD model mice and improve the inflammatory state in the brain of AD model mice.
[0018] In summary, epilupine or its derivatives can be used to prevent or treat Alzheimer's disease, improve patients' cognitive dysfunction, and enhance patients' memory. It has the advantages of significant effect, small dosage, and few side effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.
[0020] Figure 1 is the epilupine in Test Example 1 1 H NMR spectrum;
[0021] Figure 2 is the epilupine in Test Example 1 13 C NMR spectrum;
[0022] Figure 3 is the MS mass spectrum of epilupine in Experimental Example 1;
[0023] Figure 4 (A) is the number of times mice in different treatment groups crossed the platform in Experimental Example 1, and (B) is the latency time of mice in different treatment groups on the platform in Experimental Example 1;
[0024] Figure 5(A) is the total distance that mice in different treatment groups moved in Experimental Example 2, (B) is the time that mice in different treatment groups stayed in the central area in Experimental Example 2, (C) is the number of times that mice in different treatment groups crossed the central area of the platform in Experimental Example 2, and (D) is the distance that mice in different treatment groups moved in the central area in Experimental Example 2;
[0025] Figure 6 is the concentration of inflammatory factors in the brain of mice in different treatment groups in Experimental Example 3. DETAILED DESCRIPTION
[0026] The invention provides application of epilupine and its derivatives in preparing drugs for resisting Alzheimer's disease.
[0027] In the present invention, the epilupine is a white powder, HRESI-MS m / z[M+H] + 170.1539, indicating that its molecular formula is C 10 H 19 NO.
[0028] 1 H NMR (400MHz, CDCl3) δ3.73-3.46 (m, 1H), 2.86-2.68 (m, 1H), 2.01 (ddd, J = 14.6, 11.4, 2.9Hz, 1H), 1 .92-1.79(m,1H), 1.79-1.63(m,1H), 1.59(t,J=3.4Hz,1H), 1.51-1.35(m,OH), 1.30-1.09(m,1H).
[0029] 13 C NMR (100MHz, CDCl3) δ64.67, 64.31, 56.92, 56.64, 43.96, 29.78, 28.23, 25.60, 25.04, 24.58.
[0030] The chemical structural formula of epilupine is shown in Formula 1.
[0031]
[0032] In the present invention, the derivatives include organic acid or inorganic acid salt products of epilupine, and esterification products or etherification products of the 11-hydroxyl site of epilupine.
[0033] In the present invention, the medicine also includes a drug component that has a positive effect on combating Alzheimer's disease.
[0034] In the present invention, the pharmaceutical ingredients having a positive effect on combating Alzheimer's disease include acetylcholinesterase inhibitors or N-methyl-D-aspartate receptor blockers.
[0035] In the present invention, the acetylcholinesterase inhibitor includes rivastigmine, galantamine or donepezil.
[0036] In the present invention, the N-methyl-D-aspartate receptor blocker includes memantine.
[0037] In the present invention, the pharmaceutical ingredients having a positive effect on combating Alzheimer's disease also include huperzine A or mannitol.
[0038] In the present invention, the drug ingredients that have a positive effect on combating Alzheimer's disease also include Aβ or Tau protein targeting drugs.
[0039] In the present invention, the Aβ or Tau protein targeting drug includes Aducanumab, Donanemab or Lencanumab.
[0040] In the present invention, the dosage form of the drug includes powder, granules, tablets, capsules, pills, solutions, suspensions or injections.
[0041] In the present invention, the dosage form of the drug includes a liquid dosage form or a solid dosage form.
[0042] In the present invention, the liquid dosage forms include true solutions, colloids, particulate dosage forms, emulsion dosage forms, and suspension dosage forms; the solid dosage forms include tablets, capsules, pellets, aerosols, pills, powders, solutions, suspensions, emulsions, granules, suppositories, and lyophilized powder injections.
[0043] In the present invention, the tablets include sugar-coated tablets, film-coated tablets, enteric-coated tablets, double-layer tablets or multi-layer tablets.
[0044] In the present invention, the carrier of the tablet includes a diluent, a wetting agent, a disintegrant, a disintegration inhibitor, an absorption accelerator or a lubricant.
[0045] In the present invention, the diluent includes starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose or aluminum silicate; the wetting agent includes water, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate or polyvinyl pyrrolidone; the disintegrant includes dry starch, alginate, agar powder, brown seaweed starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, methyl cellulose or ethyl cellulose; the disintegration inhibitor includes sucrose, tristearin, cocoa butter or hydrogenated oil; the absorption promoter includes quaternary ammonium salt or sodium lauryl sulfate; the lubricant includes talc, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin or polyethylene glycol.
[0046] In the present invention, the capsule includes a gelatin capsule, a soft capsule or a microcapsule.
[0047] In the present invention, the carrier of the pills includes a diluent, a binder or a disintegrant.
[0048] In the present invention, the diluent includes glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinyl pyrrolidone, Gelucire, kaolin or talc; the binder includes gum arabic, tragacanth gum, gelatin, ethanol, honey, liquid sugar, rice paste or flour paste; the disintegrant includes agar powder, dry starch, alginate, sodium dodecyl sulfate, methyl cellulose or ethyl cellulose.
[0049] In the present invention, the carrier of the solution, suspension, emulsion or lyophilized powder injection includes a diluent, a binder, a lubricant, a preservative, a surfactant or a dispersant.
[0050] In the present invention, the diluent includes water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxygenated isostearyl alcohol or polyoxyethylene sorbitan fatty acid enzyme.
[0051] In the present invention, the carrier of the suppository includes polyethylene glycol, lecithin, cocoa butter, higher alcohol, enzyme of higher alcohol, gelatin or semi-synthetic glycerol enzyme.
[0052] In the present invention, the injection solution includes an isotonic injection solution, and the carrier of the isotonic injection solution includes sodium chloride, glucose, glycerol, a cosolvent, a buffer or a pH regulator.
[0053] In the present invention, the pharmaceutical preparation may include colorants, preservatives, fragrances, flavoring agents or sweeteners.
[0054] In the present invention, the administration route of the drug includes an enteral route or a parenteral route.
[0055] In the present invention, the intestinal route includes oral administration; the non-intestinal route includes intramuscular injection, subcutaneous injection, nasal cavity, oral mucosa, skin injection, acupoint injection, peritoneal or rectal route.
[0056] In the present invention, the drug can be prepared into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle delivery systems.
[0057] In the present invention, the anti-Alzheimer's disease drug includes a drug for preventing Alzheimer's disease and a drug for treating Alzheimer's disease.
[0058] In the present invention, the dosage of the drug for preventing Alzheimer's disease is 0.001-5 mg / kg·day; the dosage of the drug for treating Alzheimer's disease is 0.01-30 mg / kg·day.
[0059] In the present invention, the anti-Alzheimer's disease drug is administered orally, by nasal spray, drip or injection; the subject of administration is a mammal, including a human.
[0060] The technical solutions provided by the present invention are described in detail below in conjunction with the examples, but they should not be construed as limiting the scope of protection of the present invention. 1-EPILUPININE, CAS No.: 486-71-5, was prepared in our laboratory.
[0061] Example 1
[0062] Preparation method of epilupine:
[0063] 10 kg of Lupinus micranthus seeds were crushed, and the crushed seeds were extracted with 95% ethanol under heating and reflux for 3 times, 50 L each time, and 2 hours each time to obtain an extract; the extract was concentrated under reduced pressure to obtain an extract, a total of 2.5 kg; the obtained 2.5 kg extract was suspended in 6 L of distilled water, and the solution pH was adjusted to 2 with 2 mol / L dilute hydrochloric acid, and chloroform was used for extraction 3 times, 6 L each time; after the extraction was completed, the pH of the extracted solution was adjusted to 10 with 2 mol / L NaOH solution; after the adjustment was completed, chloroform was used for extraction 3 times, 6 L each time. The chloroform was recovered to obtain 80.0 g of total alkaloids.
[0064] The total alkaloids were crudely fractionated by silica gel column chromatography and gradient eluted with chloroform-methanol system (10:0-0:10) to obtain 6 fractions (Frs.AF), of which Fr.B (9.6 g) was separated and purified by silica gel column chromatography and Sephadex LH-20 to obtain 2 g of 1-Epilupinine.
[0065] The melting point of epilupine was determined to be 77-78°C and it is soluble in chloroform, methanol and ethanol; HR-ESI-MS m / z[M+H] + 170.1539, indicating that its molecular formula is C 10 H 19 NO.
[0066] Example 2
[0067] Take 150g of epilupine, 300g of lactose as a filler, 2.25g of magnesium stearate as a lubricant, and 4.5g of silicon dioxide as an anti-caking agent, sieve, mix, and put into capsules to prepare 1000 epilupine capsules. The content of epilupine is obtained by quantitative analysis and used as the basis for the dosage.
[0068] Example 3
[0069] 150 g of epilupeine was diluted with water and 0.15 g of stevioside was used to correct the taste to prepare a 10% epilupeine oral solution. The content of epilupeine was obtained by quantitative analysis and used as the basis for the dosage.
[0070] Example 4
[0071] Take 100 g of epilupine, dissolve it in 500 mL of anhydrous ethanol, add 3% dilute hydrochloric acid solution dropwise to pH 6, let stand to precipitate epilupine hydrochloride crystals, filter, and dry to obtain epilupine hydrochloride; add water for injection according to routine procedures, fine filter, fill, and sterilize to prepare an injection solution.
[0072] Example 5
[0073] Take 200 g of epilupine, dissolve it in 1000 mL of anhydrous ethanol, add 5% sulfuric acid ethanol solution until the pH is 6, let it stand to precipitate crystals, filter, and dry to obtain epilupine sulfate; dissolve the obtained epilupine sulfate in sterile water for injection, add 5% glucose as an excipient, stir to dissolve the epilupine sulfate, filter with a sterile suction funnel, and then filter aseptically, divide it into 2 ampoules, freeze-dry at low temperature, sterilize and seal to obtain a powder injection.
[0074] Example 6
[0075] Epilupine is mixed with excipient starch in a weight ratio of 9:1 to prepare a powder.
[0076] Example 7
[0077] Epilupine and excipient starch are mixed in a weight ratio of 1:8, and granulated and tableted.
[0078] Example 8
[0079] Dissolve 50 g of epilupine in 300 mL of anhydrous ethanol, add 3% ethanolic phosphoric acid solution dropwise until the pH is 6, allow to stand to precipitate crystals, filter, and dry to obtain epilupine phosphate; and prepare an oral liquid according to a conventional oral liquid preparation method.
[0080] Example 9
[0081] Epilupine is mixed with auxiliary materials in a weight ratio of 5:1 to prepare capsules (auxiliary materials: lactose 10% + talc 1% + starch 2%) or granules (auxiliary materials: water 5% + starch 5% + lactose 10% + talc 1%) or granules (auxiliary materials: lactose 10% + citric acid 1% + magnesium oxide 0.1% + peppermint oil 0.1%).
[0082] Example 10
[0083] Epilupine is mixed with auxiliary materials in a weight ratio of 3:1 to prepare capsules (auxiliary materials: lactose 10% + talc 1% + starch 2%) or granules (auxiliary materials: water 5% + starch 5% + lactose 10% + talc 1%) or granules (auxiliary materials: lactose 10% + citric acid 1% + magnesium oxide 0.1% + peppermint oil 0.1%).
[0084] Embodiment 11
[0085] 46.6 g of epilupine, 600 g of starch, 200 g of lactose, 3 g of menthol, and 152 g of sodium carboxymethyl starch were mixed to prepare lozenges as a functional food.
[0086] Experimental Example 1 Effect of lupine on Morris water maze exploration test of AD mouse model
[0087] Experimental animals: C57BL / 6 male mice weighing 20-30 g were selected (provided by Beijing Huafukang Biotechnology Co., Ltd., license number: SCXK (Beijing) 2020-0004). The mice were housed in separate cages, with a light / dark cycle of 12h / 12h, a temperature of 20-22°C, and free access to food and water (food was provided by Beijing Huilinzegu Biotechnology Co., Ltd.).
[0088] Experimental drug: 1-EPILUPININE (extracted from Institute of Materia Medica, Chinese Academy of Medical Sciences). The chemical purity and structural analysis of 1-EPILUPININE are as follows: Figure 1-3 As shown; Donepezil hydrochloride (5 mg) was purchased from Eisai (China) Pharmaceutical Co., Ltd.
[0089] Experimental methods: After one week of adaptive feeding, male mice were divided into 5 groups: blank control group (CON), model group (MOD), model + positive control group (M_P), model + epilupine low-dose group (M_ELP-L) and model + epilupine high-dose group (M_ELP-H), with 10 mice in each group. Among them, the M_P group was intraperitoneally injected with donepezil (solvent was 1% DMSO) at a dose of 5 mg / kg; the M_ELP-L group was intraperitoneally injected with epilupine (solvent was 1% DMSO) at a dose of 2.5 mg / kg; the M_ELP-H group was intraperitoneally injected with epilupine (solvent was 1% DMSO) at a dose of 5 mg / kg, and the CON group and MOD group were intraperitoneally injected with an equal amount of solvent (1% DMSO). All mice were given the drug once a day for 5 consecutive days.
[0090] Morris water maze test was started on the 6th day. One hour before the behavioral experiment, donepezil (solvent was 1% DMSO) was intraperitoneally injected into the M_P group at a dose of 5 mg / kg; epilupine (solvent was 1% DMSO) was intraperitoneally injected into the M_ELP-L group at a dose of 2.5 mg / kg; epilupine (solvent was 1% DMSO) was intraperitoneally injected into the M_ELP-H group at a dose of 5 mg / kg, and the CON and MOD groups were intraperitoneally injected with an equal amount of solvent (1% DMSO); 30 minutes before the behavioral experiment, all treatment groups and model groups (M_P group, M_ELP-L group, M_ELP-H group, MOD group) were intraperitoneally injected with scopolamine hydrobromide (1 mg / kg, solvent was saline), and the CON group was injected with an equal amount of saline.
[0091] First, the Morris water maze hidden platform experiment was conducted for 5 consecutive days to explore the spatial learning ability and spatial memory ability of mice. The hidden platform experiment requires that a white platform with a diameter of 8 cm be placed about 15 cm from the center of the SW-III quadrant, and the platform be hidden 1.5 cm from the liquid surface in the water maze, and the platform position be kept unchanged for 5 days. According to the four quadrants, each mouse is placed facing the pool wall in turn and gently placed in the water. The time required for the mouse to find the hidden platform is recorded and recorded as the latency (latency, s). If the mouse does not find the platform within 1 min, the experimenter will lead it to the platform and stay for 15 s. Each mouse undergoes a round of experiments in four quadrants every day, and the interval between entering the water in each quadrant is 20 min to ensure that the mouse has enough rest time. After 24 hours of the last hidden platform positioning navigation experiment, the mouse space exploration experiment was carried out. Keep the external conditions such as the control, water depth, light, temperature, and humidity unchanged, and only remove the water maze platform. The mouse is placed in the water facing the water maze pool wall of the four quadrants. The number of times the mouse crossed the platform within 60 seconds and the sum of the latency were recorded for 4 times. The more times the mouse crossed the platform and the shorter the latency, the better the drug improved memory and spatial learning ability.
[0092] Statistical methods: SPSS25.0 software was used for statistical analysis. Measurement data that conformed to the normal distribution were expressed as mean ± standard deviation (mean ± SD), and measurement data that were not normally distributed were expressed as median (interquartile range). One-way ANOVA was used to compare the means between multiple groups that conformed to the normal distribution and variance homogeneity, and the least significant difference method (LSD) was used to compare between two groups; if it did not conform to the normal distribution and variance homogeneity, non-parametric tests were performed, and the Kruskal-Wallis H rank sum test was used to compare multiple groups, and the Mann-Whitney U test was used to compare data between two groups. p < 0.05 was considered statistically significant. The statistical results are as follows Figure 4 As shown, (A) is the number of times mice in different treatment groups crossed the platform, and (B) is the latency time of mice in different treatment groups on the platform.
[0093] from Figure 4 It can be seen that compared with the blank control group (CON), the number of times the mice in the model group (MOD) crossed the platform position was significantly reduced (p < 0.001, Figure 4 (A)), and the latency was increased (p < 0.001, Figure 4 (B)), indicating that scopolamine hydrobromide (1 mg / kg) can lead to a decrease in the memory and spatial learning ability of mice. The number of times the model + epilupine high-dose group (M_ELP-H) crossed the platform position was significantly increased compared with the model group (MOD) (p = 0.007, Figure 4(A)), and the incubation period was shortened (p = 0.009, Figure 4 (B) ), indicating that 5 mg / kg of epilupine can reverse the decline in memory and spatial learning ability of mice caused by scopolamine hydrobromide (1 mg / kg), and the improvement effect is not inferior to that of donepezil hydrochloride used in the positive control group.
[0094] Test Example 2: Open field test in mice
[0095] The open field test was performed on mice the day after the Morris water maze test: 1 hour before the behavioral experiment, the M_P group was intraperitoneally injected with donepezil (solvent was 1% DMSO) at a dose of 5 mg / kg, and the M_ELP-L group was intraperitoneally injected with epilupine (solvent was 1% DMSO) at a dose of 2.5 mg / kg; the M_ELP-H group was intraperitoneally injected with epilupine (solvent was 1% DMSO) at a dose of 5 mg / kg, and the CON group and MOD group were intraperitoneally injected with an equal amount of solvent (1% DMSO); 30 minutes before the behavioral experiment, all treatment groups and model groups (M_P group, M_ELP-L group, M_ELP-H group, MOD group) were intraperitoneally injected with scopolamine hydrobromide (1 mg / kg, solvent was normal saline), and the CON group was injected with an equal amount of normal saline.
[0096] At the beginning of the experiment, the mice were placed in the open field, and the Any-maze software was used to record the activities of the mice within 10 minutes, mainly observing the time and distance the mice stayed in the central area. After the experiment was completed, the mice were taken out, the open field was cleaned, and alcohol was sprayed to remove the odor before continuing the experiment with the next mouse. The total distance the mouse moved can be used to evaluate the mouse's athletic ability. The longer the total distance of movement, the better the activity ability. The number of times and distance that the mouse entered the central area were negatively correlated with the mouse's anxiety. The shorter the stay time, the more severe the mouse's anxiety. The statistical results are as follows Figure 5 As shown, (A) is the total distance that mice in different treatment groups moved, (B) is the time that mice in different treatment groups stayed in the central area, (C) is the number of times that mice in different treatment groups crossed the central area of the platform, and (D) is the distance that mice in different treatment groups moved in the central area.
[0097] The results showed that compared with the MOD group, the total distance of mice moving decreased significantly after donepezil treatment, while there was no significant decrease in the two doses of epilupine groups, that is, epilupine treatment did not affect the motor ability of mice. Figure 5 (A)】. In addition, compared with CON mice, the number, time and distance of mice entering the central area after AD modeling (MOD group) were significantly reduced, indicating that AD model mice may have anxiety-like behavior after modeling. Although donepezil treatment (M_P group) can improve the memory of model mice, it cannot reverse this anxiety-like behavior【 Figure 5(B), (C), (D)]. After epilupine (2.5 mg / kg) treatment, the time mice entered the central area was significantly increased compared with the model group (MOD group). At the same time, compared with the M_P group, the number and distance of mice entering the central area after epilupine treatment increased significantly, which means that epilupine can alleviate anxiety-like behaviors in AD model mice. Figure 5 (B), (C), (D)].
[0098] Experimental Example 3 Detection of inflammatory factors in mouse brain
[0099] After the behavioral experiment, the mice were killed immediately, their brains were removed, and the prefrontal lobes were isolated and stored in a -80°C refrigerator.
[0100] When extracting protein, the frontal lobe was weighed and cut into pieces. The cut tissue was mixed with 500 μL lysis buffer (prepared with 10 μL protease inhibitor and 990 μL 1×Cell Lysis Buffer) for every 100 mg of tissue, added to a glass homogenizer, and ground thoroughly on ice. In order to further lyse tissue cells, the homogenate was ultrasonically disrupted. Finally, the homogenate was centrifuged at 5000×g for 10 minutes, the supernatant was taken, and the inflammatory factor antibody chip was used for detection, and the QAR-INF-1 data analysis software was used for data analysis. The detection and analysis results are shown in the figure. Figure 6 shown.
[0101] from Figure 6 It can be seen that the levels of proinflammatory factors GM-CSF, INF-g, IL-2, and IL-23 in mice treated with high-dose and low-dose epilupine were lower than those in the model group, and the difference between the high-dose group and the model group was significant, indicating that epilupine has the effect of reducing inflammatory factors in the mouse brain.
[0102] As can be seen from the above examples, the present invention provides the use of epilupine and its derivatives in the preparation of anti-Alzheimer's disease drugs. Epilupine or its derivatives can be used to prevent or treat Alzheimer's disease, improve patients' cognitive dysfunction, and improve patients' memory, and has the advantages of significant effect, small dosage, and small side effects.
[0103] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Use of epilupine as the sole active ingredient in the preparation of an anti-Alzheimer's disease drug, wherein the structural formula of the epilupine is:
2. The use according to claim 1, characterized in that The medicine also includes a pharmaceutical ingredient that has a positive effect against Alzheimer's disease.
3. The use according to claim 2, characterized in that The pharmaceutical ingredients having a positive effect on combating Alzheimer's disease include acetylcholinesterase inhibitors or N-methyl-D-aspartate receptor blockers.
4. The use according to claim 3, characterized in that The acetylcholinesterase inhibitors include rivastigmine, galantamine or donepezil.
5. The use according to claim 3, characterized in that The N-methyl-D-aspartate receptor blockers include memantine.
6. The use according to claim 2, characterized in that The drug ingredients that have a positive effect on combating Alzheimer's disease also include huperzine A or mannitol.
7. The use according to claim 2, characterized in that The drug ingredients that have a positive effect on combating Alzheimer's disease also include Aβ or Tau protein targeting drugs.
8. The use according to claim 7, characterized in that The Aβ or Tau protein targeting drugs include Aducanumab, Donanemab or Lencanemab.
